Combining Apelin inhibition (genetically or using an inactive Apelin agonist) with anti‐angiogenic therapy using different small molecular weight kinase inhibitors (sunitinib, axitinib) led to marked delay in breast cancer growth in mice. The gene discussed is APLN; the disease is breast cancer.